Jorge Adeva

2.6k total citations
21 papers, 358 citations indexed

About

Jorge Adeva is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jorge Adeva has authored 21 papers receiving a total of 358 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 14 papers in Surgery and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jorge Adeva's work include Cholangiocarcinoma and Gallbladder Cancer Studies (13 papers), Pancreatic and Hepatic Oncology Research (11 papers) and Gallbladder and Bile Duct Disorders (5 papers). Jorge Adeva is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (13 papers), Pancreatic and Hepatic Oncology Research (11 papers) and Gallbladder and Bile Duct Disorders (5 papers). Jorge Adeva collaborates with scholars based in Spain, United Kingdom and United States. Jorge Adeva's co-authors include Juan W. Valle, Adelaida La Casta, Mitesh J. Borad, Rossana Berardi, Jordi Bruix, Milind Javle, Bruno Sangro, Julien Edeline, Massimiliano Salati and Ghassan K. Abou‐Alfa and has published in prestigious journals such as Journal of Clinical Oncology, Hepatology and Cancer Research.

In The Last Decade

Jorge Adeva

17 papers receiving 353 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jorge Adeva Spain	9	234	201	119	82	42	21	358
Yu Nakaji Japan	11	213 0.9×	230 1.1×	214 1.8×	99 1.2×	39 0.9×	28	501
K Tamás Netherlands	2	143 0.6×	265 1.3×	56 0.5×	56 0.7×	40 1.0×	4	344
Takuro Mizukami Japan	12	91 0.4×	213 1.1×	175 1.5×	152 1.9×	73 1.7×	48	427
Shinobu Tomochika Japan	9	108 0.5×	125 0.6×	70 0.6×	56 0.7×	72 1.7×	39	285
Igor Djurisic Serbia	10	130 0.6×	90 0.4×	60 0.5×	75 0.9×	73 1.7×	31	325
Fabrizio Scognamillo Italy	10	106 0.5×	121 0.6×	51 0.4×	56 0.7×	56 1.3×	35	300
Cédric Lecaille France	11	123 0.5×	284 1.4×	143 1.2×	46 0.6×	69 1.6×	21	449
Yasuhiro Yabushita Japan	10	155 0.7×	170 0.8×	114 1.0×	34 0.4×	41 1.0×	41	290
Kazuharu Igarashi Japan	12	171 0.7×	144 0.7×	100 0.8×	79 1.0×	47 1.1×	31	327
Tenghui Ma China	11	203 0.9×	231 1.1×	73 0.6×	60 0.7×	34 0.8×	37	371

Countries citing papers authored by Jorge Adeva

Since Specialization

Citations

This map shows the geographic impact of Jorge Adeva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jorge Adeva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jorge Adeva more than expected).

Fields of papers citing papers by Jorge Adeva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jorge Adeva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jorge Adeva. The network helps show where Jorge Adeva may publish in the future.

Co-authorship network of co-authors of Jorge Adeva

This figure shows the co-authorship network connecting the top 25 collaborators of Jorge Adeva. A scholar is included among the top collaborators of Jorge Adeva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jorge Adeva. Jorge Adeva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Adeva, Jorge, et al.. (2025). SEOM-GEMCAD-TTD clinical guidelines for biliary tract cancer (2025). Clinical & Translational Oncology. 27(8). 3293–3306.

Martín, Andrés J. Muñoz, et al.. (2025). MDM2 amplification in a real-world cohort of patients with biliary tract cancer from the Spanish RETUD gastrointestinal registry. PubMed. 8. 100187–100187.

Martín, Andrés J. Muñoz, Florian Castet, Jorge Adeva, et al.. (2025). MDM2 amplification in patients with biliary tract cancer in RETUD registry.. Journal of Clinical Oncology. 43(4_suppl). 615–615.

Maderer, Annett, Daniel‐Christoph Wagner, Mairéad G. McNamara, et al.. (2025). 320P First-line therapy (1L) of cisplatin/gemcitabine (CisGem) with pembrolizumab (pembro) in patients with advanced biliary tract cancer (aBTC): Open-label, single-arm phase II EORTC-1607-GITCG/ABC-09 intergroup study with translational research (TR). Annals of Oncology. 36. S124–S125. 1 indexed citations

Pacheco-Barcía, Vilma, Alberto Carmona‐Bayonas, Javier Gállego, et al.. (2024). Nutritional impact and prognostic role of systemic inflammatory response index (SIRI) in advanced pancreatic cancer: PANTHEIA-Spanish Society of Medical Oncology (SEOM) study results.. Journal of Clinical Oncology. 42(3_suppl). 623–623. 1 indexed citations

Javle, Milind, Ghassan K. Abou‐Alfa, Teresa Macarulla, et al.. (2022). Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Interim results from the phase 2 study FIDES-01.. Journal of Clinical Oncology. 40(4_suppl). 427–427. 29 indexed citations

Vera, Ruth, et al.. (2022). Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer. Clinical & Translational Oncology. 24(11). 2107–2119. 4 indexed citations

Zhu, Andrew X., Teresa Macarulla, Milind Javle, et al.. (2021). Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.. Journal of Clinical Oncology. 39(3_suppl). 266–266. 38 indexed citations

Abou‐Alfa, Ghassan K., Teresa Macarulla, Milind Javle, et al.. (2021). Final results from ClarIDHy, a global, phase 3, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.. Journal of Clinical Oncology. 39(15_suppl). 4069–4069. 1 indexed citations

10.

Díaz-García, C. Vanesa, Virginia Pardo, Inés García‐Consuegra, et al.. (2021). Tumor–Stromal Interactions in a Co-Culture Model of Human Pancreatic Adenocarcinoma Cells and Fibroblasts and Their Connection with Tumor Spread. Biomedicines. 9(4). 364–364. 12 indexed citations

11.

Auclin, Édouard, Perrine Vuagnat, Cristina Smolenschi, et al.. (2021). Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors. Cancers. 13(15). 3776–3776. 8 indexed citations

12.

Lamarca, Ángela, Álvaro Santos‐Laso, Kirsten Utpatel, et al.. (2020). Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System. Hepatology. 73(6). 2311–2325. 42 indexed citations

13.

Santos‐Laso, Álvaro, Ángela Lamarca, Adelaida La Casta, et al.. (2019). SAT-485-European cliolangiocarcinoma (EU-CCA) registry: An initiative to broaden awareness on the second most common primary liver cancer. Journal of Hepatology. 70(1). e846–e847.

14.

Abou‐Alfa, Ghassan K., T. Macarulla Mercadé, Milind Javle, et al.. (2019). ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. Annals of Oncology. 30. v872–v873. 69 indexed citations

15.

Adeva, Jorge, Bruno Sangro, Massimiliano Salati, et al.. (2019). Medical treatment for cholangiocarcinoma. Liver International. 39(S1). 123–142. 64 indexed citations

16.

Cala, Mónica P., M. Teresa Agulló-Ortuño, Carolina González-Riaño, et al.. (2018). Multiplatform plasma fingerprinting in cancer cachexia: a pilot observational and translational study. Journal of Cachexia Sarcopenia and Muscle. 9(2). 348–357. 66 indexed citations

17.

Álvarez, Rafael, Alfredo Carrato, Jorge Adeva, et al.. (2018). Management of hyperbilirubinaemia in pancreatic cancer patients. European Journal of Cancer. 94. 26–36. 8 indexed citations

18.

Martín, Andrés J. Muñoz, et al.. (2017). Pancreatic ductal adenocarcinoma: metastatic disease. Clinical & Translational Oncology. 19(12). 1423–1429. 7 indexed citations

19.

Agulló-Ortuño, M. Teresa, Carlos A. Perez, C. Vanesa Díaz-García, et al.. (2015). Abstract 2575: Pharmacodynamic evaluation of the combination of carboplatin and paclitaxel associated with either pioglitazone or hydroxyurea, within a randomized phase 1 dose escalation clinical trial in patients with advanced solid tumors. Cancer Research. 75(15_Supplement). 2575–2575. 1 indexed citations

20.

García‐Alfonso, Pilar, et al.. (2011). Safety and efficacy of first-line XELIRI with or without bevacizumab in patients with metastatic colorectal cancer: Analysis of two phase II studies.. Journal of Clinical Oncology. 29(4_suppl). 560–560. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact